What is a key screening question for anthracycline exposure?

What is a key screening question for anthracycline exposure?

• A. Whether a patient has a history of heart disease
• B. Whether a patient has ever received anthracycline chemotherapy
• C. Whether the patient currently experiences chest pain
• D. Whether the patient has had radiation therapy

Answer: (B)

The main idea is that screening for anthracycline exposure hinges on asking whether the patient has ever received anthracycline chemotherapy, because exposure is the primary factor that determines risk for cardiotoxicity and informs how you monitor the heart. If a patient has been treated with an anthracycline, clinicians anticipate potential cardiac effects, monitor function (often with baseline and follow-up echocardiograms), and consider dose-related risk over time. Asking about heart disease, current chest pain, or prior radiation therapy can illuminate overall cardiac risk, but they don’t specifically identify whether the patient has been exposed to the drug that carries this particular cardiotoxic risk. Chest pain is a symptom, not exposure, and while chest radiation can affect the heart, it doesn’t answer whether anthracyclines were given. So the most direct and informative screening question is whether the patient has ever received anthracycline chemotherapy.

The main idea is that screening for anthracycline exposure hinges on asking whether the patient has ever received anthracycline chemotherapy, because exposure is the primary factor that determines risk for cardiotoxicity and informs how you monitor the heart. If a patient has been treated with an anthracycline, clinicians anticipate potential cardiac effects, monitor function (often with baseline and follow-up echocardiograms), and consider dose-related risk over time. Asking about heart disease, current chest pain, or prior radiation therapy can illuminate overall cardiac risk, but they don’t specifically identify whether the patient has been exposed to the drug that carries this particular cardiotoxic risk. Chest pain is a symptom, not exposure, and while chest radiation can affect the heart, it doesn’t answer whether anthracyclines were given. So the most direct and informative screening question is whether the patient has ever received anthracycline chemotherapy.